<table>
<thead>
<tr>
<th>Document Type</th>
<th>Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Index Number</td>
<td>Registry 109</td>
</tr>
<tr>
<td>Version Number</td>
<td>N/A</td>
</tr>
<tr>
<td>Title</td>
<td>DRAFT Disease status HCT CT IST Day0 v0.0</td>
</tr>
<tr>
<td>Author</td>
<td>Annelot van Amerongen</td>
</tr>
<tr>
<td>Authorised By</td>
<td>N/A</td>
</tr>
<tr>
<td>Authorised On</td>
<td>N/A</td>
</tr>
<tr>
<td>Release Date:</td>
<td>N/A</td>
</tr>
</tbody>
</table>
DISEASE STATUS AT HCT/CT/IST
Day 0

PATIENT STATUS
(All Diagnoses)

Date of HCT/CT/IST: __/__/__(YYYY/MM/DD)
(or planned date of HCT/CT/IST if patient died before)

Survival status at HCT/CT/IST:
☐ Alive
☐ Died after conditioning but before HCT/CT/IST
☐ Died after apheresis but before cell infusion

Date of death: __/__/__(YYYY/MM/DD)

Main cause of death:
(check only one main cause)
☐ Relapse or progression/persistent disease
☐ Secondary malignancy
☐ Cellular therapy-related
☐ HCT-related
☐ Unknown
☐ Other; specify: ____________

Select treatment related cause:
☐ Graft versus host disease
☐ Non-infectious complication
☐ Infectious complication:
☐ Bacterial infection
☐ Viral infection
☐ Fungal infection
☐ Parasitic infection
☐ Infection with unknown pathogen

Performance status at initiation of HCT/CT/IST (choose only one):
Type of scale used: Score:
☐ Karnofsky
☐ Lansky
☐ 10  20  30  40  50  60  70  80  90  100
☐ ECOG
☐ 0  1  2  3  4

Patient weight at initiation of HCT/CT/IST: _____________ kg

Patient height at initiation of HCT/CT/IST: _____________ cm
### COMORBIDITY INDEX


**Was there any clinically significant co-existing disease or organ impairment as listed below at time of patient assessment prior to the preparative regimen?**

- [ ] No
- [ ] Yes (indicate each comorbidity below)
- [ ] Unknown

#### COMORBIDITY:

<table>
<thead>
<tr>
<th>Condition</th>
<th>Definition</th>
<th>No</th>
<th>Yes</th>
<th>Not evaluated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solid tumour, previously present</td>
<td>Treated at any time point in the patient's past history, excluding non-melanoma skin cancer. Indicate type:__________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>Crohn's disease or ulcerative colitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatologic</td>
<td>SLE, RA, polymyositis, mixed CTD or polymyalgia rheumatica</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>Requiring continuation of antimicrobial treatment after day 0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>Requiring treatment with insulin or oral hypoglycaemics but not diet alone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal: moderate/severe</td>
<td>Serum creatinine &gt; 2 mg/dL or &gt;177 μmol/L, on dialysis, or prior renal transplantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic: mild</td>
<td>Chronic hepatitis, bilirubin between Upper Limit Normal (ULN) and 1.5 × ULN, or AST/ALT between ULN and 2.5 × ULN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic: moderate/severe</td>
<td>Liver cirrhosis, bilirubin greater than 1.5 × ULN, or AST/ALT greater than 2.5 × ULN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arrhythmia</td>
<td>Atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>Coronary artery disease, congestive heart failure, myocardial infarction, EF ≤ 50%, or shortening fraction in children (&lt;28%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>Transient ischaemic attack or cerebrovascular accident</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart valve disease</td>
<td>Except mitral valve prolapse</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary: moderate</td>
<td>DLco and/or FEV1 66-80%, or dyspnoea on slight activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary: severe</td>
<td>DLco and/or FEV1 ≤ 65%, or dyspnoea at rest or requiring oxygen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>Patients with body mass index &gt; 35 kg/m²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peptic ulcer</td>
<td>Requiring treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric disturbance</td>
<td>Depression or anxiety requiring psychiatric consultation or treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COMORBIDITY INDEX continued

Was there any additional major clinical abnormality not listed above and present prior to the preparative regimen?

☐ No
☐ Yes; specify: ________________________

Were there any autoimmune diseases?

☐ No
☐ Yes; specify: ________________________

Date: _ _ _ / _ _ _ / _ _ _ (YYYY/MM/DD)

COMORBIDITY INDEX
Inborn Errors of Immunity only

<table>
<thead>
<tr>
<th>COMORBIDITY:</th>
<th>Definition:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic lung disease</td>
<td>Bronchiectasis, interstitial pneumonitis, GLILD, oxygen dependency, structural lung disease (e.g. pneumatoceles)</td>
</tr>
<tr>
<td>Previous haematological malignancy</td>
<td>Leukaemia, lymphoma, myelodysplastic syndrome (MDS)</td>
</tr>
<tr>
<td>Failure to thrive</td>
<td>Weight &lt;3rd percentile or requirement for (par)enteral feeding</td>
</tr>
<tr>
<td>Active infection at HCT</td>
<td>Any infection requiring therapy in the immediate pre HCT period</td>
</tr>
<tr>
<td>Lymphoproliferation</td>
<td>I.e. splenomegaly, organ specific lymphoproliferation</td>
</tr>
<tr>
<td>Pre-HCT organ impairment</td>
<td>Infectious or non-infectious (including neurologic)</td>
</tr>
<tr>
<td>Autoimmunity/autoinflammation</td>
<td>Active at HCT (includes patients in remission but on immunomodulatory treatment within 3 months before HCT)</td>
</tr>
</tbody>
</table>
SARS-CoV-2 RELATED QUESTIONS

Did the patient have a symptomatic SARS-CoV-2 infection (positive PCR or antigen test) in the 3 months prior to the day of treatment? Note: do not report here if the infection was asymptomatic.

☐ No
☐ Yes; Date: _ _ _ _ / _ _ / _ _ (YYYY/MM/DD)

Did the patient have an ongoing SARS-CoV-2 infection (positive PCR or antigen test) at the moment of the start of the conditioning regimen?

☐ No
☐ Yes

END OF GENERAL SECTION

TO COMPLETE DISEASE STATUS AT HCT/CT/IST REPORT, PLEASE FILL IN THE APPLICABLE DIAGNOSE-SPECIFIC QUESTIONS ATTACHED
Status at treatment

Complete only for one main indication diagnosis for which this HCT/CT/IST is given.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACUTE LEUKAEMIAS</td>
<td>Go to page 6</td>
</tr>
<tr>
<td>CHRONIC LEUKAEMIAS - Chronic Myelogenous Leukaemias (CML)</td>
<td>Go to page 7</td>
</tr>
<tr>
<td>CHRONIC LEUKAEMIAS - Chronic Lymphocytic Leukaemias (CLL)</td>
<td>Go to page 8</td>
</tr>
<tr>
<td>CHRONIC LEUKAEMIAS - Prolymphocytic (PLL) and Other Chronic Leukaemias</td>
<td>Go to page 9</td>
</tr>
<tr>
<td>LYMPHOMAS</td>
<td>Go to page 10</td>
</tr>
<tr>
<td>MYELODYSPLASTIC SYNDROMES (MDS)</td>
<td>Go to page 11</td>
</tr>
<tr>
<td>COMBINED MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS (MDS/MPN)</td>
<td>Go to page 12</td>
</tr>
<tr>
<td>MYELOPROLIFERATIVE NEOPLASMS (MPN)</td>
<td>Go to page 13</td>
</tr>
<tr>
<td>PLASMA CELL DISORDERS (PCD) including MULTIPLE MYELOMA (MM)</td>
<td>Go to page 15</td>
</tr>
<tr>
<td>SOLID TUMOURS</td>
<td>Go to page 16</td>
</tr>
<tr>
<td>AUTOIMMUNE DISEASES</td>
<td>Go to page 17</td>
</tr>
<tr>
<td>HAEMOGLOBINOPATHIES</td>
<td>Go to page 18</td>
</tr>
</tbody>
</table>
ACUTE LEUKAEMIAS
Status at treatment

Status:
☐ Primary induction failure
☐ 1st complete haematological remission (CR)
☐ 1st relapse
☐ 2nd complete haematological remission (CR)
☐ 2nd relapse
☐ 3rd or higher complete haematological remission (CR)
☐ 3rd or higher relapse
☐ Unknown

Number of induction courses: ____  ☐ Unknown

Date of the last relapse before this treatment: ___ / ___ / ___ (YYYY/MM/DD)  ☐ Not applicable
(if applicable)

CD19 expression at the last relapse: ☐ Positive  ☐ Negative  ☐ Not evaluated

Bone marrow burden (% blasts): ____ %  ☐ Not evaluated  ☐ Unknown

Involvement at time of treatment:
☐ Medullary only
☐ Extra-medullary only
☐ Both, medullary and extra-medullary
☐ Unknown

Organs involved at time of treatment:

Skin:  ☐ No  ☐ Yes  ☐ Not evaluated
CNS:  ☐ No  ☐ Yes  ☐ Not evaluated
Testes/Ovary:  ☐ No  ☐ Yes  ☐ Not evaluated
Other; specify: __________  ☐ No  ☐ Yes

Complete this section only if the disease status is CR

Minimal residual disease (MRD) at initiation of treatment:
☐ Positive
☐ Negative
☐ Not evaluated

Date MRD status evaluated: ___ / ___ / ___ (YYYY/MM/DD)

Sensitivity of MRD assay:
☐ <10⁻⁵
☐ <10⁻⁴
☐ <10⁻³
☐ Other; specify: __________

Method used:
☐ PCR
☐ Flow cytometry
☐ Other; specify: 
### Chronic Myelogenous Leukaemias (CML) - Status at treatment

<table>
<thead>
<tr>
<th>Status:</th>
<th>Chronic phase (CP)</th>
<th>Accelerated phase</th>
<th>Blast crisis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1st</td>
<td>1st</td>
<td>1st</td>
</tr>
<tr>
<td></td>
<td>2nd</td>
<td>2nd</td>
<td>2nd</td>
</tr>
<tr>
<td></td>
<td>3rd or higher</td>
<td>3rd or higher</td>
<td>3rd or higher</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haematological remission:</th>
<th>No</th>
<th>Yes</th>
<th>Not evaluated</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytogenetic remission:</td>
<td>No</td>
<td>Yes</td>
<td>Not evaluated</td>
<td>Unknown</td>
</tr>
<tr>
<td>Molecular remission:</td>
<td>No</td>
<td>Yes</td>
<td>Not evaluated</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

This is an uncontrolled copy.
CHRONIC LEUKAEMIAS
Chronic Lymphocytic Leukaemias (CLL) - Status at treatment

Status:

☐ Complete remission (CR)
☐ Partial remission (PR)
☐ Stable disease (SD)
☐ Relapse (untreated)
☐ Progressive disease (PD)
☐ Never treated
☐ Unknown

Complete this section only if the disease status is CR

- Minimal residual disease (MRD) at initiation of treatment:
  (by FACS or PCR)
  ☐ Negative
  ☐ Positive
  ☐ Not evaluated
CHRONIC LEUKAEMIAS
Prolymphocytic (PLL) and Other Chronic Leukaemias
Status at treatment

Status:

- Complete remission (CR)
- Partial remission (PR)
- Stable disease (SD)
- Relapse (untreated)
- Progressive disease (PD)
- Never treated
- Unknown
**LYMPHOMAS**

Status at treatment

<table>
<thead>
<tr>
<th>Status</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete remission (CR)</td>
<td></td>
</tr>
<tr>
<td>□ Unconfirmed (CRU*)</td>
<td></td>
</tr>
<tr>
<td>□ Confirmed</td>
<td></td>
</tr>
<tr>
<td>* CRU: Complete response with persistent scan abnormalities of unknown significance</td>
<td></td>
</tr>
<tr>
<td>Partial response (PR) with or without prior CR</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>□ Stable disease</td>
<td></td>
</tr>
<tr>
<td>□ Untreated relapse from previous CR / untreated progression from previous PR</td>
<td></td>
</tr>
<tr>
<td>□ Histopathological verification of relapse: No</td>
<td></td>
</tr>
<tr>
<td>□ Yes</td>
<td></td>
</tr>
<tr>
<td>□ Chemorefractory relapse or progression, including primary refractory disease</td>
<td></td>
</tr>
<tr>
<td>□ Histopathological verification of relapse: No</td>
<td></td>
</tr>
<tr>
<td>□ Yes</td>
<td></td>
</tr>
<tr>
<td>□ Disease status unknown</td>
<td></td>
</tr>
</tbody>
</table>

**Technique used for disease assessment:**
- CT scan
- PET
- MRI

**Parameters for international prognostic indices:**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis:</td>
<td>_____ years (this is automatically calculated in the database)</td>
</tr>
<tr>
<td>LDH levels elevated:</td>
<td>No</td>
</tr>
<tr>
<td>Ann Arbor staging:</td>
<td>I</td>
</tr>
<tr>
<td>ECOG performance status:</td>
<td>0</td>
</tr>
<tr>
<td>&gt; 1 extranodal site involved:</td>
<td>No</td>
</tr>
<tr>
<td>&gt; 4 nodal sites involved:</td>
<td>No</td>
</tr>
<tr>
<td>Hemoglobin &lt; 120g/L:</td>
<td>No</td>
</tr>
<tr>
<td>White Blood Cell count:</td>
<td>_____ x 10⁹ cells/L</td>
</tr>
</tbody>
</table>
### MYELODYSPLASTIC SYNDROMES (MDS)
#### Status at treatment

**Classification at treatment (WHO 2016):**

- [ ] MDS with single lineage dysplasia (MDS-SLD)
- [ ] MDS with ring sideroblasts (MDS-RS)
- [ ] Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
- [ ] MDS with multilineage dysplasia (MDS-MLD)
- [ ] MDS-RS with single lineage dysplasia (MDS-RS-SLD)
- [ ] MDS-RS with multilineage dysplasia (MDS-RS-MLD)
- [ ] MDS with excess blasts (EB)-1
- [ ] MDS with excess blasts (EB)-2
- [ ] Refractory cytopenia of childhood
- [ ] MDS unclassifiable (MDS-U)

**Status:**

- [ ] Complete remission (CR)  
  - [ ] 1st
  - [ ] 2nd
  - [ ] 3rd or higher
  - [ ] Unknown

- [ ] Improvement but no CR

- [ ] Primary refractory phase (no change)

- [ ] Relapse  
  - [ ] 1st
  - [ ] 2nd
  - [ ] 3rd or higher
  - [ ] Unknown

- [ ] Progression/Worsening

- [ ] Never treated (supportive care or treatment without chemotherapy)

- [ ] Unknown
COMBINED MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS (MDS/MPN) - Status at treatment

Classification:

☐ Chronic myelomonocytic leukaemia (CMMoL, CMML): CMML type:
  ☐ Myelodysplastic
  ☐ Myeloproliferative

WHO subclassification (2016):
  ☐ CMML-0
  ☐ CMML-1
  ☐ CMML-2
  ☐ Unknown

☐ Juvenile myelomonocytic leukaemia (JCMMoL, JMMML, JCML, JCML)

☐ Atypical CML (t(9;22) negative and BCR-ABL1 negative)

☐ MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)

☐ MDS/MPN unclassifiable

Status:

☐ Complete remission (CR)
  ☐ 1st
  ☐ 2nd
  ☐ 3rd or higher
  ☐ Unknown

☐ Improvement but no CR

☐ Primary refractory phase (no change)

☐ Relapse
  ☐ 1st
  ☐ 2nd
  ☐ 3rd or higher
  ☐ Unknown

☐ Progression/Worsening

☐ Never treated (supportive care or treatment without chemotherapy)

☐ Unknown
MYELOPROLIFERATIVE NEOPLASMS (MPN)
Status at treatment

**Classification at treatment (WHO 2016):**

- [ ] Primary myelofibrosis (Chronic idiopathic myelofibrosis; fibrosis with myeloid metaplasia)
- [ ] Secondary myelofibrosis (Transformed to myelofibrosis from PV/ET)
- [ ] Polycythaemia vera (PV)
- [ ] Essential or primary thrombocythaemia (ET)
- [ ] Hyper eosinophilic syndrome (HES)
- [ ] Chronic eosinophilic leukaemia (CEL)
- [ ] Chronic neutrophilic leukaemia
- [ ] Systemic mastocytosis
- [ ] Mast cell leukaemia
- [ ] Mast cell sarcoma
- [ ] MPN not otherwise specified
- [ ] Myeloid and lymphoid neoplasms with FGFR1 abnormalities (Stem cell leukaemia-lymphoma syndrome, 8p11 syndrome)
- [ ] Myeloid and lymphoid neoplasms with PDGFRα rearrangement
- [ ] Myeloid and lymphoid neoplasms with PDGFRB rearrangement
- [ ] Myeloid and lymphoid neoplasms with PCM1-JAK2 rearrangement
- [ ] Transformed to AML
- [ ] Other; specify: ____________

**Status:**

- [ ] Complete remission (CR)
  - Number:
    - [ ] 1st
    - [ ] 2nd
    - [ ] 3rd or higher
    - [ ] Unknown
- [ ] Improvement but no CR
- [ ] Primary refractory phase (no change)
- [ ] Relapse
  - Number:
    - [ ] 1st
    - [ ] 2nd
    - [ ] 3rd or higher
    - [ ] Unknown
- [ ] Progression/Worsening
- [ ] Never treated (supportive care or treatment without chemotherapy)
- [ ] Unknown
# MYELOPROLIFERATIVE NEOPLASMS (MPN)
## Status at treatment

<table>
<thead>
<tr>
<th>Blast count (peripheral blood):</th>
<th>%</th>
<th>Not evaluated</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen size: cm (below costal margin)</td>
<td></td>
<td>Not evaluated</td>
<td>Unknown</td>
</tr>
<tr>
<td>Spleen span in ultrasound or CT scan: cm (maximum diameter)</td>
<td></td>
<td>Not evaluated</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### JAK inhibitor exposure between diagnosis and treatment:
- No
- Yes
- Unknown

### Was a JAK inhibitor continued during conditioning?
- No
- Yes: Dose: mg/day
  - Start date: _ _ _ / _ _ / _ _ (YYYY/MM/DD)
  - End date: _ _ _ / _ _ / _ _ (YYYY/MM/DD)

### Response status:
- Spleen response
- No response/loss of response
- Primary resistance
- Unknown

### Myelofibrosis only:

#### DIPSS Risk score at treatment:
- Low risk
- Intermediate - 1
- Intermediate - 2
- High risk
- Not evaluated
- Unknown

#### MIPSS70 score at treatment:
- Low risk
- Intermediate
- High risk
- Not evaluated
- Unknown

### Secondary myelofibrosis only (post-ET MF, post-PV MF):

#### MYSEC-PM score at time of secondary MF diagnosis:
- Low risk
- Intermediate - 1
- Intermediate - 2
- High risk
- Not evaluated
- Unknown
PLASMA CELL DISORDERS (PCD) incl. MULTIPLE MYELOMA (MM)
Status at treatment

<table>
<thead>
<tr>
<th>Status</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRD negative CR</td>
<td></td>
</tr>
<tr>
<td>Stringent complete remission (sCR)</td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td></td>
</tr>
<tr>
<td>Very good partial remission (VGPR)</td>
<td></td>
</tr>
<tr>
<td>Partial remission (PR)</td>
<td></td>
</tr>
<tr>
<td>Stable disease / No change</td>
<td></td>
</tr>
<tr>
<td>Progression</td>
<td></td>
</tr>
<tr>
<td>Never treated</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>
### SOLID TUMOURS

**Status at treatment**

<table>
<thead>
<tr>
<th>Status:</th>
<th>Number:</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Adjuvant</td>
<td></td>
</tr>
<tr>
<td>□ Never treated (upfront)</td>
<td>1&lt;sup&gt;st&lt;/sup&gt;</td>
</tr>
<tr>
<td>□ Stable disease/no response</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt;</td>
</tr>
<tr>
<td>□ Complete remission (CR)</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; or higher</td>
</tr>
<tr>
<td>□ Unconfirmed (UCR*)</td>
<td>Unknown</td>
</tr>
<tr>
<td>□ Confirmed</td>
<td></td>
</tr>
</tbody>
</table>

* UCR: complete response with persistent scan abnormalities of unknown significance

| Test: 1<sup>st</sup> partial response (PR1)                             |
|------------------------------------------------------------------------|----------|
| □ Relapse                                                              |          |
| □ Progressive disease (PD)                                             |          |
| □ Unknown                                                              | 1<sup>st</sup> |
| □ Unknown                                                              | 2<sup>nd</sup> |
| □ Unknown                                                              | 3<sup>rd</sup> or higher |
| □ Unknown                                                              | Unknown  |

---

**Organ involvement at time of this treatment:**

- Nodes below diaphragm
- Nodes above diaphragm
- CNS
- Liver
- Bone
- Lung
- Soft tissue
- Other; specify: __________________________

---

**Germ cell tumours only:**

**Risk category at disease recurrence (or platinum refractoriness) following first line chemotherapy:**

- Very low
- Low
- Intermediate
- High
- Very high
- Not evaluated

---

*Complete this section only if the disease status is not CR*
### Autoimmune Diseases
**Status at Mobilisation**

#### Systemic sclerosis only:

**SSc subset:**
- [ ] Diffuse cutaneous
- [ ] Limited cutaneous
- [ ] Sine scleroderma
- [x] Other; specify: __________________

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- Creatinine Clearance (Cockcroft formula): ______________ ml/min  [ ] Unknown
- Proteinuria: ______________ g/24hrs  [ ] Unknown
- Modified Rodnan Skin Score (0-51): ______________  [ ] Unknown
- DLCO (corrected for Hb): ______________ %  [ ] Unknown
- Mean Pulmonary Arterial Systolic Pressure [PASP] (from right heart catheterisation): ______________ mm Hg
- GI Involvement:  [ ] No  [ ] Yes  [ ] Not evaluated  [ ] Unknown

#### Systemic lupus erythematosus only:

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- SLEDAI-2K Score: ____________  [ ] Not evaluated  [ ] Unknown

#### Multiple sclerosis only:

**Status at time of mobilisation (within 3 months before mobilisation):**

- [ ] Primary progressive
- [ ] Secondary progressive
- [ ] Relapsing/remitting
- [ ] Other; specify: __________________

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- EDSS (1-10): ____________  [ ] Not evaluated
- Number of gadolinium enhancing lesions present on MRI brain scan: ______________  [ ] Unknown

#### Crohn's disease only:

**Assessments at time of mobilisation (within 3 months before mobilisation):**

- CDAI (0-700): ____________  [ ] Not evaluated  [ ] Unknown
- Serum albumin: ______________ g/L  [ ] Unknown
# HAEMOGLOBINOPATHIES
## Status at treatment

**Ferritin level**: ______ ng/mL  
- [ ] Not evaluated  
- [ ] Unknown

**Number of red blood cell transfusions**:  
- [ ] < 20 units  
- [ ] 20 to 50 units  
- [ ] > 50 units  
- [ ] None  
- [ ] Unknown

**Liver iron concentration**: ______ mg/g dry weight

### Pre-existing liver disease?
- [ ] No
- [ ] Yes: **Hepatitis**:  
  - [ ] Absent  
  - [ ] Chronic persistent hepatitis  
  - [ ] Chronic active hepatitis

**Liver biopsy performed**:  
- [ ] No
- [ ] Yes: **Liver fibrosis ( Ishak staging)**:  
  - [ ] F0 (no fibrosis)  
  - [ ] F1 (partial fibrosis)  
  - [ ] F2 (general fibrosis)  
  - [ ] F3 (partial bridging in fibrosis)  
  - [ ] F4 (general bridging in fibrosis)  
  - [ ] F5 (near cirrhosis)  
  - [ ] F6 (cirrhosis)

### Pre-existing cardiac disease?
- [ ] No
- [ ] Yes: **Cardiac echography ejection fraction**:  
  - [ ] No  
  - [ ] Yes

**Cardiovascular magnetic resonance (CMR) T2**: ______ mg/g dry weight

---

**Sickle cell disease only**

**Chronic transfusion program**:  
- [ ] No  
- [ ] Yes
HAEMOGLOBINOPATHIES
Status at treatment

Pre-treatment complications (Sickle cell disease only):
(check all that apply)

- **Cerebrovascular disease**
  - Abnormal Doppler: □ No □ Yes □ Not evaluated
  - Stroke: □ No □ Yes □ Not evaluated
  - Haemorrhage: □ No □ Yes □ Not evaluated
  - Arteriopathy: □ No □ Yes □ Not evaluated
  - Moyamoya disease: □ No □ Yes □ Not evaluated
  - Silent infarcts: □ No □ Yes □ Not evaluated

- **Renal involvement**
  - Microalbumin level: □ mg/g □ Not evaluated
  - Glomerular filtration rate: □ mL/min/1.73m² □ Not evaluated
  - Avascular necrosis: □ No □ Yes □ Not evaluated
  - Hyperhaemolysis or autoimmune haemolytic anaemia:
    - □ No
    - □ Yes: □ Hyperhaemolysis □ Autoimmune haemolytic anaemia
    - □ Not evaluated

- **Other SCD related complications**
  - Acute chest syndrome: □ No □ Yes □ Not evaluated
  - Vaso-occlusive crisis: □ No □ Yes □ Not evaluated
  - Priapism: □ No □ Yes □ Not evaluated
  - Pulmonary artery pressure: □ No □ Yes □ Not evaluated
  - Chronic lung disease: □ No □ Yes □ Not evaluated

Endocrinopaties pre-existing to HCT (Thalassemia only):

- Hypothyroidism: □ No □ Yes □ Not evaluated
- Hypoparathyroidism: □ No □ Yes □ Not evaluated
- Diabetes mellitus: □ No □ Yes □ Not evaluated
- Osteoporosis: □ No □ Yes □ Not evaluated
- Gonadal dysfunction: □ No □ Yes □ Not evaluated
- Growth impairment: □ No □ Yes □ Not evaluated

Index: Registry 109 | Title: DRAFT Disease status HCT CT IST Day0 v0.0 | Version: 0.0 | Effective Date: | THIS IS AN UNCONTROLLED COPY